source
- Vertex completes $10 billion Crinetics acquisition as Q3 M&A slowsM&A activity in the pharmaceutical sector cooled in the third quarter, with total deal value just under $30 billion across 22 transactions, according to BioSpace. Vertex Pharmaceuticals completed…
- Kallyope rebrands as TriGemX Bio, secures $94M to fund Phase 3 migraine trialKallyope, a New York City drug developer, announced it is changing its name to TriGemX Bio as it narrows its pipeline to migraine. The rebrand follows a recent partnership with Novo on an obesity…